Komori
Management planning4527ROHTO PHARMACEUTICAL CO.,LTD.Pharmaceuticals

“Medium- to Long-Term Growth Strategy 2026” Revised on 5 October

A revised version has been published, but the body does not specify which parts of the original material were corrected or how. In the body, the previous FY2030 forecast has been raised to revenue of ¥444 billion and operating profit of ¥56.8 billion, and the target fiscal year has been rolled forward to FY2031.

Worth reading
50Recurring
Scored from 2 of 3 sections
Direction
Mixed performance
Direction inferred from the company’s description.
Scale
290
¥100 million (increase in FY2030 revenue)
Wording
Avoiding a definitive answer
How definitive the wording is.

The document this correction applies to

Timely disclosure
"Medium- to Long-Term Growth Strategy 2026"2026-10-02

What was corrected and how

A subsequent correction by the company to the contents of an already published filing.

Original disclosure2 October 2026

"Medium- to Long-Term Growth Strategy 2026"

Open the original document
3 daysThe pre-correction wording stayed published for this period (Calculated from the Original Disclosure Date Indicated in the Document)
This correction2026-10-05
Before correction

FY2030: Revenue of ¥415 billion, operating profit of ¥54 billion, operating margin of 13%, and EBITDA of 18.2%

After correction

FY2030: Revenue of ¥444 billion and operating profit of ¥56.8 billion. The target fiscal year has also been revised to FY2031, for which forecasts of revenue of ¥464 billion, operating profit of ¥59.8 billion, and an operating margin of 12.9% are provided.

ChangesFY2030 revenue increased by ¥29 billion and operating profit by ¥2.8 billion
What was corrected and how
ItemDetails
Disclosure subject to correction"Medium- to Long-Term Growth Strategy 2026"
Original disclosure date2 October 2026
Details of correctionFY2030: Revenue of ¥415 billion, operating profit of ¥54 billion, operating margin of 13%, and EBITDA of 18.2% → FY2030: Revenue of ¥444 billion and operating profit of ¥56.8 billion. The target fiscal year has also been revised to FY2031, for which forecasts of revenue of ¥464 billion, operating profit of ¥59.8 billion, and an operating margin of 12.9% are provided.
Items this document does not state (3)
Location of correctionReason for correctionImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The reason for the correction itself is not stated. As background to the update, the company explains that it has adopted a rolling approach, under which management forecasts are reviewed regularly to respond to an era of rapid change and uncertainty.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
“Medium- to Long-Term Growth Strategy 2026” Revised on 5 October | ROHTO PHARMACEUTICAL CO.,LTD. (4527) timely disclosure | Komori